SmartHeart is part of Philips’ growing portfolio of AI-enabled cardiac MR innovations, designed to expand patient access and improve diagnostic precision. (Photo: Philips)
March 6, 2026 — Building on its leadership in cardiac MR, Philips has received FDA 510(k) clearance for SmartHeart, an AI-powered cardiac MR planning solution designed to simplify one of the most technically demanding MRI exams. SmartHeart automates the planning process in under 30 seconds, helping make cardiac MR more consistent and accessible.
One-click Planning
SmartHeart fully automates 14 standard and advanced cardiac views in less than 30 seconds.* Trained on more than 1,200 cardiac MR datasets, the AI engine is engineered to provide reliable performance across a range of patient anatomies and follow-up scenarios.
By eliminating repetitive manual adjustments, SmartHeart helps reduce operator variability and improve workflow consistency, making cardiac MR more accessible to technologists with varying experience levels.
“Cardiac MR is one of the most powerful tools available to assess the heart, yet its complexity and exam length have historically constrained its broader clinical impact,” said Ioannis Panagiotelis, PhD, Business Leader MR at Philips. “With SmartHeart embedded directly into the planning workflow, Philips is fundamentally redefining how CMR is performed — transforming it from a highly specialized, time-intensive procedure into a streamlined, intelligent, and scalable solution." He added, "This empowers clinicians to deliver consistent, precision cardiac care to significantly more patients.”
Supporting Patient Comfort
For the patient, SmartHeart can reduce the number of breath holds for basic views by up to 75%, supporting comfort, particularly for individuals with dyspnea, arrhythmias, pediatric patients, or anxiety, while helping departments increase throughput with existing staff and scanners.
Part of Philips’ full AI-enabled cardiac MR suite
SmartHeart is part of Philips’ growing portfolio of AI-enabled cardiac MR innovations, designed to expand patient access and improve diagnostic precision. Now with 510(k) clearance, the suite is now approved for clinical use in the U.S., with additional innovations including:
- CINE FreeBreathing – Enabling diagnostic-quality imaging without the need for breath-holds, helping improve comfort for patients who cannot hold their breath or have irregular heart rhythms.
- Cardiac Motion Correction (Cardiac MoCo) – Correcting for both cardiac and respiratory motion to deliver robust insights for a more definitive diagnosis.
- CardiacQuant Perfusion– Providing non-invasive, non-ionizing quantitative assessment of myocardial perfusion, which can support clinicians in the diagnosis of subtle perfusion deficits more objectively.
Precision Cardiac Care
As cardiac disease remains a leading cause of morbidity, broader access to high-quality cardiac MR may enable earlier detection, more confident diagnosis, and more proactive management of heart conditions.
By simplifying planning and reducing dependence on operator expertise, Philips’ AI-enabled cardiac MR suite helps cardiology and radiology departments increase productivity without compromising diagnostic quality. Faster setup, fewer breath holds, and consistent planning supports a more comfortable patient experience and more efficient use of imaging resources.
Click here to learn more.
Sources
* Patient datasets from the Netherlands, the USA and India
Additional Philips information
April 20, 2026 
